

(Patient Sticker)



PHYSICIAN ORDER SET : **Densumbab (Prolia)**

CDH 208-273 - Approved - Page 1 of 3

Patient:	DOB:	Gender:				
Patient Phone #:	Height:	Weight:				
Diagnosis:	ICD-10 Code:					
Treatment Start Date:						
Provider Facility Name:	Provider Facility Address:					
Ordering Provider:	Date:					
Signature:						
Please include H&P/current medications list/allergies, and ensure that med authorizations have been obtained Because of the risk of hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, serious infections, and dermatologic reactions, denosumab (Prolia) is provided through a REMS Program. By signing this plan you will be ordering denosumab and attesting that you are aware of the risk, that the medication is clinically necessary, and that you have counseled and will monitor the patient for denosumab-associated toxicities.						
Criteria to Treat CA greater than: 8.4 25-OH Vitamin D greater than: 20 If Vit D is less than 20, review provider documentation that it is okal Infusion. If documentation not found, contact the provider.	Interval Every Visit	Defer Until	Duration 1 treatment			
Medications						
☐ Denosumab (PROLIA) 60 mg/mL subcutaneous sy 60 mg, Subcutaneous, Once, Starting at treatment start time	ringe 60 mg Every 26 Weeks	Defer Until	Duration 1 treatment			
Catheter management						
☐ Line Access Routine, Once, Starting S For 1 Occurrences, As needed. Starting	Interval PRN when released. Until Specified.	Defer Until	Duration PRN			

Insert peripheral IV, or access peripheral, or central venous access device, to provide treatment.

	Mass General Brigham Cooley Dickinson Hospital		(Patient Sticker)	
	PHYSICIAN ORDER SET : Densumbab (Prolia)			
	CDH 208-273 — Approved - Page 2 of 3			
the	ter management (continued)			
		Interval	Defer Until	Duration
	sodium chloride (NS) 0.9 % syringe flush 3 mL 3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Star	PRN ting when released	d	PRN
	sodium chloride 0.9% infusion 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide treatment, Sta	PRN rting when release	ed	PRN
er	gency Medications			
		Interval	Defer Until	Duration
	Provider and Nurse Communication Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wh saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY m	emergency persor	nnel, administer oxyg	
	EPINEPHrine (ADRENALIN) injection 0.3 mg	PRN	,	PRN
	0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. I	May repeat times 1	I dose, Starting wher	n released.
	For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is equiv	alent to 1 mg/mL		
	sodium chloride 0.9% bolus 1,000 mL	PRN		PRN
	1,000 mL, Intravenous, Once as needed, Hypotension, Starting when released, Fo	r 1 dose		
	Oxygen Therapy - Non-Rebreather Routine Select a Mode of Therapy: Non-Rebreather Titrate Oxygen and use the most appropriate device to maintain Target Oxygen sa	PRN turation during Act	ivity/titration: Yes	PRN
	Min Sp02 (%): 94	-		
e	rsensitivity			
		Interval	Defer Until	Duration
	Provider and Nurse Communication Routine, Until discontinued, Starting when released Treatment for mild-moderate in emergency personnel, administer oxygen as needed, monitor vital signs and proce If ANAPHYLAXIS reaction, refer to Emergency Medications section.			
	albuterol nebulizer solution 2.5 mg/ 3mL (0.083%)	PRN		PRN
	2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, s	shortness of breath	n, Starting when relea	ased, For 1 dose
	acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting at treatment start time, For 1 dose	PRN		PRN
	diphenhydrAMINE (BENADRYL) injection 25 mg	PRN		PRN
	25 mg, Intravenous, As needed, itching, itching, hive or adjunct treatment for mild-r for 2 doses. Begin with 25 mg. If patient has continued reaction, administer addition		ERE reaction, Starting	g when released
	methylprednisolone sodium succinate (PF) (SOLU-Medrol) injection 40 mg 40 mg, Intravenous, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting when released, For 1 dose. To be administered along with antihistamine and famotidine.			PRN
	famotidine (PF)(PEPCID) injection 20 mg	PRN		PRN
_	20 mg intravenous. Once as needed. Adjunct treatment for mild-moderate, or SEVI administered along with H1 antihistamine and methylprednisolone. HOLD IF given	as premed.	rting when released.	
Ш	 ondansetron (ZOFRAN) injection 4 mg 4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 does, Starting whe 	PRN en		PRN

10 mg, Oral, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting at treatment start time, For 1 dose. If patient unable to tolerate cetirizine, administer fexofenadine if available. HOLD IF giving fexofenadine.

PRN

PRN

released, For 2 doses

☐ cetirizine (ZyrTEC) tablet 10 mg

Mass General Brigham Cooley Dickinson Hospital	(Patient Sticker)
PHYSICIAN ORDER SET : Densumbab (Prolia)	
CDH 208-273 — Approved - Page 3 of 3	

Hypersensitivity (continued)

	Interval De	efer Until Duration
☐ fexofenadine (ALLEGRA) tablet 180 mg	PRN	PRN

180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting at treatment Start time, for 1 dose. Administer only if unable to tolerate cetirizine.

HOLD IF giving cetirizine.

version 6/25/2024